Keywords
prevention
public health
Colombia
How to Cite
Abstract
Chronic kidney disease (CKD) is a highly prevalent entity in developing countries, affecting a large part of the Colombian population, which affects the quality of life, longevity and health costs. It has a progressive and irreversible character, so that intervening in early stages, turns out to be a highly cost-effective measure, from this, the concept of nephro-prevention arises, in which taking into account the levels of primary, secondary and tertiary prevention, it is possible to obtain an early identification, interruption or slowing down of progression, and timely and comprehensive management of kidney damage according to the stage of their disease, taking into account an active search for cases, carrying out screening tests and an interdisciplinary intervention that includes education of the population and health personnel, in order to generate self-care and follow-up that positively impacts quality of life, outcomes and finally the economy of developing countries, which those who, with limited resources, must optimize and invest in the processes that generate greater cost-effectiveness.
References
Acuña L, Sánchez P, Soler LA, Alvis LF. Enfermedad renal en Colombia: Prioridad para la gestión de riesgo. Rev Panam Salud Publica/Pan Am J Public Heal. 2016;40(1):16-22.
Cueto-Manzano AM, Martínez-Ramírez HR, Cortés-Sanabria L, Rojas-Campos E. The Role of Primary Health Care Professionals. In: Chronic Kidney Disease in Disadvantaged Populations. Elsevier Inc.; 2017:329-335. doi: http://dx.doi.org/10.1016/B978-0-12-804311-0.00031-5
Garcia-Garcia G, Jha V. Chronic kidney disease in disadvantaged populations. Indian J Nephrol. 2015;25(2):65-69. doi: http://dx.doi.org/10.4103/0971-4065.150078
Cusumano AM, Rosa-Diez GJ, Gonzalez-Bedat MC. Latin American Dialysis and Transplant Registry: Experience and contributions to end-stage renal disease epidemiology. World J Nephrol. 2016;5(5):389. doi: http://dx.doi.org/10.5527/wjn.v5.i5.389
Naicker S. End-stage renal disease in sub-Saharan Africa. Ethn Dis. 2009;19(1 Suppl 1): S1-13-15.
Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018; 392(10159): 2052-2090. Doi: http://dx.doi.org/10.1016/S0140-6736(18)31694-5
Merkin SS, Diez Roux A V, Coresh J, Fried LF, Jackson SA, Powe NR. Individual and neighborhood socioeconomic status and progressive chronic kidney disease in an elderly population: The Cardiovascular Health Study. Soc Sci Med. 2007;65(4):809-821. doi: http://dx.doi.org/10.1016/j.socscimed.2007.04.011
Colombia, Ministerio de Salud y Protección Social, Ministerio de Hacienda y Crédito Público. Cuenta de Alto Costo: Fondo Colombiano de Enfermedades de alto Costo. Situación de la enfermedad renal, hipertensión arterial y diabetes mellitus en Colombia [Internet]. Bogotá: Ministerio de Salud y Protección Social; 2017. Disponible en: https://cuentadealtocosto.org/site/publicaciones/situacion-de-la-enfermedad-renal-cronica-la-hipertension-arterial-y-la-diabetes-mellitus-en-colombia-2017/?1584310319210
Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant. 2008;23(4):1216-1223. doi: http://dx.doi.org/10.1093/ndt/gfn082
Camargo JA, Vargas JG, D´Achiardi R, Echeverri JE. Factores de riesgo para la progresión de enfermedad renal crónica en pacientes con nefropatía diabética estadios 3 y 4 del Servicio de Nefrología del Hospital Militar Central de Bogotá. Rev Colomb Nefrol. 1969;1(0 SE-Artículos). Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/146.
Jungers P. Late referral: loss of chance for the patient, loss of money for society. Nephrol Dial Transplant. 2002;17(3):371-375. doi: http://dx.doi.org/10.1093/ndt/17.3.371
Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis. 1998;31(3):398-417. doi: http://dx.doi.org/10.1053/ajkd.1998.v31.pm9506677
Mathew T, Corso O. Review article: Early detection of chronic kidney disease in Australia: which way to go? Nephrology (Carlton). 2009;14(4):367-373. doi: http://dx.doi.org/10.1111/j.1440-1797.2009.01113.x
Luxardo R, Kramer A, Gonzalez-Bedat MC, Massy ZA, Jager KJ, Rosa-Diez G, et al. The epidemiology of renal replacement therapy in two different parts of the world: the Latin American Dialysis and Transplant Registry versus the European Renal Association-European Dialysis and Transplant Association Registry. Rev Panam Salud Publica. 2018;42: e87. doi: http://dx.doi.org/10.26633/RPSP.2018.87
Cueto-Manzano AM, Martínez-Ramírez HR, Cortés-Sanabria L. Management of chronic kidney disease: Primary health-care setting, self-care and multidisciplinary approach. Clin Nephrol. 2010;74(SUPPL.1):99-104. doi: http://dx.doi.org/10.5414/cnp74s099
Cueto-Manzano AM, Martínez-Ramírez HR, Cortés-Sanabria L. Comparison of primary health-care models in the management of chronic kidney disease. Kidney Int Suppl. 2013;3(2):210-214. doi: http://dx.doi.org/10.1038/kisup.2013.16
National Kidney Foundation. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 (2 Suppl 1): S1-266).
Idney Disease: Improving Global Outcomes (KDIGO) CKD Work GroupKDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2012;3(1):1-150. doi: http://dx.doi.org/10.1038/kisup.2012.76
Grupo de trabajo de la Guía de Práctica Clínica sobre la Detección y el Manejo de laEnfermedad Renal Crónica. Guía de Práctica Clínica sobre la Detección y el Manejo de laEnfermedad Renal Crónica. Madrid: Ministerio de Sanidad Servicios Sociales e Igualdad;2016 [citado abril 12 2020]. Disponible en: https://portal.guiasalud.es/wp-content/uploads/2018/12/GPC559ERCIACScompl.pdf .
Webster AC, Nagler E V., Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017;389(10075):1238-1252. doi: http://dx.doi.org/10.1016/S0140-6736(16)32064-5
Chang A, Kramer H. CKD progression: a risky business. Nephrol Dial Transplant. 2012;27(7):2607-2609. doi: http://dx.doi.org/10.1093/ndt/gfs095
Goldstein SL, Devarajan P. Acute kidney injury in childhood: ¿should we be worried about progression to CKD? Pediatr Nephrol. 2011;26(4):509-522. doi: http://dx.doi.org/10.1007/s00467-010-1653-4
Mirrakhimov AE. Obstructive sleep apnea and kidney disease: ¿is there any direct link? Sleep Breath. 2012;16(4):1009-1016. doi: http://dx.doi.org/10.1007/s11325-011-0624-8
Hsiao LL. Raising awareness, screening and prevention of chronic kidney disease: It takes more than a village. Nephrology. 2018; 23:107-111. doi: http://dx.doi.org/10.1111/nep.13459
Song E-Y, McClellan WM, McClellan A, Gadi R, Hadley A, Krisher J, et al. Effect of community characteristics on familial clustering of end-stage renal disease. Am J Nephrol. 2009;30(6):499-504. doi: http://dx.doi.org/10.1159/000243716
Iseki K. Factors influencing the development of end-stage renal disease. Clin Exp Nephrol. 2005;9(1):5-14. doi: http://dx.doi.org/10.1007/s10157-005-0341-3
Li PK-T, Garcia-Garcia G, Lui S-F, Andreoli S, Fung WW, Hradsky A, et al. Kidney Health for Everyone Everywhere: From Prevention to Detection and Equitable Access to care. Clin Nephrol. 2020 Mar;93(3):111-122. doi: http://dx.doi.org/10.14740/wjnu402
Kalantar-Zadeh K, Fouque D. Nutritional Management of Chronic Kidney Disease. N Engl J Med. 2017;377(18):1765-1776. doi: http://dx.doi.org/10.1056/NEJMra1700312
Caggiani Malzone M, Halty Alcoba M. Conceptos de nefroprevención. Arch pediatr Urug. 2009;80(3):215-218.
Centers for Disease Control and Prevention (CDC). Picture of America: Kindey Chro-nic Disease. Atlanta: CDC; 2019 [citado april 7 2020]. Disponible en: https://www.cdc.gov/pictureofamerica/pdfs/PictureofAmericaChronicKidneyDisease.pdf
Martínez-Ramírez HR, Cortés-Sanabria L, Rojas-Campos E, Barragán G, Alfaro G, Hernández M, et al. How frequently the clinical practice recommendations for nephropathy are achieved in patients with type 2 diabetes mellitus in a primary health-care setting?. Rev Invest Clin. 2008;60 (3):217-226.
Cortes-Sanabria L, Cabrera-Pivaral CE, Cueto-Manzano AM, Rojas-Campos E, Barragán G, Hernández-Anaya M, et al. Improving care of patients with diabetes and CKD: a pilot study for a cluster-randomized trial. Am J Kidney Dis. 2008;51(5):777-788. doi: http://dx.doi.org/10.1053/j.ajkd.2007.12.039
Verhave JC, Troyanov S, Mongeau F, Fradette L, Bouchard J, Awadalla P, et al. Prevalence, awareness, and management of CKD and cardiovascular risk factors in publicly funded health care. Clin J Am Soc Nephrol. 2014;9(4):713-719. doi: http://dx.doi.org/10.2215/CJN.06550613
Tantisattamo E, Dafoe DC, Reddy UG, Ichii H, Rhee CM, Streja E, et al. Current Management of Patients With Acquired Solitary Kidney. Kidney Int reports. 2019;4(9):1205-1218. doi: http://dx.doi.org/10.1016/j.ekir.2019.07.001
Ene-Iordache B, Perico N, Bikbov B, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Heal. 2016;4(5):e307-19. doi: http://dx.doi.org/10.1016/S2214-109X(16)00071-1
Colombia. Ministerio de Salud y Protección Social (MinSalud). Colombia si-gue avanzando en la cobertura universal en salud. Bogotá D.C.: MinSalud;2020[citadomayo15].Disponibleen:https://www.minsalud.gov.co/Paginas/Colombia-sigue-avanzando-en-la-cobertura-universal-en-salud-.aspx#:~:text=%E2%80%8B%2D%20Ante%20la%20OMS%2C%20el,la%20regi%C3%B3n%20de%20las%20am%C3%A9ricas.
Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014;63(5):789-797. doi: http://dx.doi.org/10.1053/j.ajkd.2013.12.012
Harris D, Thomas M, Johnson D, Nicholls K GA. The CARI Guidelines-Caring for Australians with renal impairment. Prevention of Progression of Kidney Disease. Dietary protein restriction; 2004.
Cueto-Manzano AM, Cortes-Sanabria L, Martínez-Ramírez HR, Rojas-Campos EE. Enfermedad Renal Crónica Temprana, Prevención, Diagnóstico y Tratamiento. In: Editorial Panamericana, eds. México; 2013:59–64.
Feehally J, Brusselmans A, Finkelstein FO, Harden P, Harris D, Manuzi G, et al. Improving global health: measuring the success of capacity building outreach programs: a view from the International Society of Nephrology. Kidney Int Suppl. 2016;6(2):42-51. doi: http://dx.doi.org/10.1016/j.kisu.2016.09.002
Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Engelgau M, et al. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2002;39(3):445-459. doi: http://dx.doi.org/10.1053/ajkd.2002.31388
Amato D, Alvarez-Aguilar C, Castaneda-Limones R, Rodriguez E, Avila-Diaz M, Arreola F, et al. Prevalence of chronic kidney disease in an urban Mexican population. Kidney Int Suppl. 2005;(97):S11-7. doi: http://dx.doi.org/10.1111/j.1523-1755.2005.09702.x
Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane database Syst Rev. 2014;(6):CD007333. doi: http://dx.doi.org/10.1002/14651858.CD007333.pub2
Lopera Vargas JM, Rico Fontalvo JE, Melgarejo E, Castillo Barrios GE, Ramírez Rincón A, Gomez AM, et al. Efecto de terapias farmacológicas para el control glicémico en pacientes con Diabetes Mellitus tipo 2 en los desenlaces vasculares. Rev Colomb Nefrol. 2020;7(1). Doi: http://dx.doi.org/10.22265/acnef.7.1.372
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi: http://dx.doi.org/10.1056/NEJMoa1504720
Arocha-Rodulfo JI, Amair P, Marantes D, Navas-Blanco T. El papel del riñón en la ho-meostasis de la glucosa y drogas de acción renal en el tratamiento de la diabetes mellitustipo 2. Med Interna (Caracas). 2016;32(2):78-88
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. doi: http://dx.doi.org/10.1056/NEJMoa1611925
Coulter A, Ellins J. Effectiveness of strategies for informing, educating, and involving patients. BMJ. 2007;335(7609):24-27. doi: http://dx.doi.org/10.1136/bmj.39246.581169.80
Organización Mundial de la Salud (OMS). Informe sobre la salud en el mundo. La atención primaria de salud, más necesaria que nunca [Internet]. Ginebra: OMS; 2008 [cited 7 april 2020]. Disponible en: https://www.who.int/whr/2008/es/
Cueto-Manzano AM, Gallardo-Rincón H, Martínez-Ramírez HR, Cortés-Sanabria L, Rojas-Campos E, Tapia-Conyer R, et al. A pilot study of a mobile phone application to improve lifestyle and adherence of patients with kidney disease. J Telemed Telecare. 2015;21(2):119-120. doi: http://dx.doi.org/10.1177/1357633X14566591
Diamantidis CJ, Ginsberg JS, Yoffe M, Lucas L2, Prakash D3, Aggarwal S, et al. Remote Usability Testing and Satisfaction with a Mobile Health Medication Inquiry System in CKD. Clin J Am Soc Nephrol. 2015;10(8):1364-1370. doi: http://dx.doi.org/10.2215/CJN.12591214
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.